OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, et al.
Behavioural Neurology (2016) Vol. 2016, pp. 1-6
Open Access | Times Cited: 46
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, et al.
Behavioural Neurology (2016) Vol. 2016, pp. 1-6
Open Access | Times Cited: 46
Showing 1-25 of 46 citing articles:
Cannabidiol - a friend or a foe?
Bianca-Maria Tihăuan, Tatiana Onisei, Walter Slootweg, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107036-107036
Open Access | Times Cited: 1
Bianca-Maria Tihăuan, Tatiana Onisei, Walter Slootweg, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107036-107036
Open Access | Times Cited: 1
Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms
Palanisamy Sivanandy, Tan Choo Leey, Tan Chi Xiang, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 19, Iss. 1, pp. 364-364
Open Access | Times Cited: 49
Palanisamy Sivanandy, Tan Choo Leey, Tan Chi Xiang, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 19, Iss. 1, pp. 364-364
Open Access | Times Cited: 49
Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Nicholas Aderinto, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 4, pp. 80-80
Open Access | Times Cited: 4
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Nicholas Aderinto, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 4, pp. 80-80
Open Access | Times Cited: 4
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine
Gabriel Moreno, Rhea Gandhi, Stephanie Lessig, et al.
Neurology (2018) Vol. 91, Iss. 17, pp. 797-799
Open Access | Times Cited: 36
Gabriel Moreno, Rhea Gandhi, Stephanie Lessig, et al.
Neurology (2018) Vol. 91, Iss. 17, pp. 797-799
Open Access | Times Cited: 36
Evidence-Based Review of Pharmacotherapy Used for Parkinson’s Disease Psychosis
Kyle John Wilby, Eric Johnson, Hannah E. Johnson, et al.
Annals of Pharmacotherapy (2017) Vol. 51, Iss. 8, pp. 682-695
Closed Access | Times Cited: 34
Kyle John Wilby, Eric Johnson, Hannah E. Johnson, et al.
Annals of Pharmacotherapy (2017) Vol. 51, Iss. 8, pp. 682-695
Closed Access | Times Cited: 34
Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases
Amarendranath Choudhury, Tripti Sahu, Praveena L. Ramanujam, et al.
Neuropsychiatry (2018) Vol. 08, Iss. 01
Open Access | Times Cited: 33
Amarendranath Choudhury, Tripti Sahu, Praveena L. Ramanujam, et al.
Neuropsychiatry (2018) Vol. 08, Iss. 01
Open Access | Times Cited: 33
<p>Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis</p>
Han Zhang, Limin Wang, Yafei Fan, et al.
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 2137-2149
Open Access | Times Cited: 32
Han Zhang, Limin Wang, Yafei Fan, et al.
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 2137-2149
Open Access | Times Cited: 32
Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson’s Disease Psychosis: An Update
Sapna Rao, Lisa J. McQuay, Joan Forns, et al.
Drug Safety (2025)
Open Access
Sapna Rao, Lisa J. McQuay, Joan Forns, et al.
Drug Safety (2025)
Open Access
Drug Treatment of Psychiatric Symptoms Occurring in the Context of Other Conditions
(2025), pp. 803-864
Closed Access
(2025), pp. 803-864
Closed Access
Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
J. Bradley Layton, Joan Forns, Mary Ellen Turner, et al.
Drugs - Real World Outcomes (2021) Vol. 9, Iss. 1, pp. 9-22
Open Access | Times Cited: 21
J. Bradley Layton, Joan Forns, Mary Ellen Turner, et al.
Drugs - Real World Outcomes (2021) Vol. 9, Iss. 1, pp. 9-22
Open Access | Times Cited: 21
Parkinson’s disease psychosis associated with accelerated multidomain cognitive decline
Sara Pisani, Luca Gosse, Dag Aarsland, et al.
BMJ Mental Health (2024) Vol. 27, Iss. 1, pp. e301062-e301062
Open Access | Times Cited: 3
Sara Pisani, Luca Gosse, Dag Aarsland, et al.
BMJ Mental Health (2024) Vol. 27, Iss. 1, pp. e301062-e301062
Open Access | Times Cited: 3
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
Brianna Combs, Arthur G. Cox
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 737-744
Open Access | Times Cited: 27
Brianna Combs, Arthur G. Cox
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 737-744
Open Access | Times Cited: 27
Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis
Yasaman Kianirad, Tanya Simuni
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 11, pp. 1161-1168
Closed Access | Times Cited: 26
Yasaman Kianirad, Tanya Simuni
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 11, pp. 1161-1168
Closed Access | Times Cited: 26
Palliative medicine and end-of-life care
Toni L. Glover, Benzi M. Kluger
Handbook of clinical neurology (2019), pp. 545-561
Closed Access | Times Cited: 23
Toni L. Glover, Benzi M. Kluger
Handbook of clinical neurology (2019), pp. 545-561
Closed Access | Times Cited: 23
Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
Cristina Miguélez, Abdelhamid Benazzouz, Luisa Ugedo, et al.
Frontiers in Cellular Neuroscience (2017) Vol. 11
Open Access | Times Cited: 20
Cristina Miguélez, Abdelhamid Benazzouz, Luisa Ugedo, et al.
Frontiers in Cellular Neuroscience (2017) Vol. 11
Open Access | Times Cited: 20
Mechanical Plantar Foot Stimulation in Parkinson′s Disease: A Scoping Review
Lorenzo Brognara, Omar Cauli
Diseases (2020) Vol. 8, Iss. 2, pp. 12-12
Open Access | Times Cited: 18
Lorenzo Brognara, Omar Cauli
Diseases (2020) Vol. 8, Iss. 2, pp. 12-12
Open Access | Times Cited: 18
A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease
John R. Younce, Albert A. Davis, Kevin J. Black
Journal of Parkinson s Disease (2018) Vol. 9, Iss. 1, pp. 63-71
Open Access | Times Cited: 15
John R. Younce, Albert A. Davis, Kevin J. Black
Journal of Parkinson s Disease (2018) Vol. 9, Iss. 1, pp. 63-71
Open Access | Times Cited: 15
Anticholinergic and sedative medication use in older community‐dwelling people: A national population study in the Netherlands
Helene G. van der Meer, Katja Taxis, Martina Teichert, et al.
Pharmacoepidemiology and Drug Safety (2019) Vol. 28, Iss. 3, pp. 315-321
Open Access | Times Cited: 11
Helene G. van der Meer, Katja Taxis, Martina Teichert, et al.
Pharmacoepidemiology and Drug Safety (2019) Vol. 28, Iss. 3, pp. 315-321
Open Access | Times Cited: 11
QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
Yasar Torres‐Yaghi, Amelia Carwin, Jacob Carolan, et al.
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 3791-3818
Open Access | Times Cited: 10
Yasar Torres‐Yaghi, Amelia Carwin, Jacob Carolan, et al.
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 3791-3818
Open Access | Times Cited: 10
Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments
Milagros Rojas, Mervin Chávez-Castillo, Pablo Durán, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 33, pp. 2725-2741
Closed Access | Times Cited: 7
Milagros Rojas, Mervin Chávez-Castillo, Pablo Durán, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 33, pp. 2725-2741
Closed Access | Times Cited: 7
Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
Rajesh Pahwa, Stuart Isaacson, Gary W. Small, et al.
Neurology and Therapy (2022) Vol. 11, Iss. 4, pp. 1571-1582
Open Access | Times Cited: 7
Rajesh Pahwa, Stuart Isaacson, Gary W. Small, et al.
Neurology and Therapy (2022) Vol. 11, Iss. 4, pp. 1571-1582
Open Access | Times Cited: 7
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson’s Disease
Kristina Rosqvist, Per Odin
Parkinson s Disease (2023) Vol. 2023, pp. 1-11
Open Access | Times Cited: 4
Kristina Rosqvist, Per Odin
Parkinson s Disease (2023) Vol. 2023, pp. 1-11
Open Access | Times Cited: 4
Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies
Manraj Bhamra, Anto P. Rajkumar, Dominic ffytche, et al.
BMJ Case Reports (2018), pp. bcr-224710
Open Access | Times Cited: 10
Manraj Bhamra, Anto P. Rajkumar, Dominic ffytche, et al.
BMJ Case Reports (2018), pp. bcr-224710
Open Access | Times Cited: 10
The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson’s disease
Jonathan Hindmarsh, Sharlene Hindmarsh, Mark Lee, et al.
Palliative Medicine (2018) Vol. 33, Iss. 1, pp. 109-113
Open Access | Times Cited: 9
Jonathan Hindmarsh, Sharlene Hindmarsh, Mark Lee, et al.
Palliative Medicine (2018) Vol. 33, Iss. 1, pp. 109-113
Open Access | Times Cited: 9
